| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Appropriate control of the immune response is extremely important to induce a beneficial effect on the whole body without harm. In this study, we obtained new groups of antibodies against Fc receptor-like 3 (FCRL3) and TNF receptor 2 (TNFR2), which have important roles in the regulation of human regulatory T cell function. We identified binding epitopes associated with the agonistic activity or antagonistic activity against TNFR2 by our unique "epitope-normalized antibody panel" technology. The obtained anti-TNFR2 antagonist antibody suppresses the proliferation and function of regulatory T cells and may be developed as a new type of immune checkpoint inhibitor.
|
